No Data
No Data
No Data
No Data
No Data
Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
Seeking AlphaApr 23 22:29
Private Equity Firms Among Solid Biosciences Inc.'s (NASDAQ:SLDB) Largest Stockholders and Were Hit After Last Week's 13% Price Drop
Key Insights Solid Biosciences' significant private equity firms ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 5 investors have a majorit
Simply Wall StApr 11 22:25
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, t
Solid BiosciencesApr 3 12:00
Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label
Solid Biosciences (SLDB) said Monday its gene therapy candidate SGT-003 for Duchenne muscular dystrophy has received rare pediatric disease designation from the US Food and Drug Administration. The de
MT NewswiresApr 2 02:04
Solid Biosciences Receives Rare Pediatric Disease Designation From the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. –– Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 –CHARLESTOWN, Mass., Apri
Solid BiosciencesApr 1 12:00
Solid Biosciences Initiated at Outperform by William Blair
Solid Biosciences Initiated at Outperform by William Blair
Dow JonesMar 28 22:52
No Data
No Data